- Reports: ESI may start 'price war' over new hepatitis C drugs
- Walgreens collaborates with CDC on comprehensive HIV treatment model
- Study: Pharmacist intervention improves shingles vaccine rate
- Study: Whooping cough vaccine may not prevent infection
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
PITTSBURGH — Mylan subsidiary Matrix Labs has expanded its licensing agreement with Gilead Sciences.
Under the new terms, Mylan said that Matrix has the rights to produce and market generic versions of three Gilead HIV/AIDS therapies — elvitegravir, an investigational integrase inhibitor; cobicistat, an investigational antiretroviral boosting agent; and the “quad,” a once-daily, single-tablet combination of four separate Gilead medicines — if and when the drugs receive regulatory approval.
“Every patient living with HIV/AIDS has a right to treatment,” Mylan president Heather Bresch said. “Matrix has made a significant contribution to dramatically lowering the cost of HIV/AIDS medicines, and we are now focused on expanding access to high-quality treatment to more people who need it. We are pleased to expand our collaboration with Gilead as it will enable more individuals living with HIV/AIDS in resource-limited countries to access the newest innovative medicines.”